What is a compounding pharmacy legally allowed to tell me, and what does it have to refuse?

I asked a compounding pharmacy three questions by email: which manufacturer supplies their API, whether their preparation is equivalent to the branded product, and whether it is FDA approved. I got one answer, one non-answer, and one answer that I am fairly sure was wrong.

They named the API supplier's country but not the company. They said their preparation "delivers the same active ingredient as the brand". And they said "all our ingredients are FDA registered", which sounds like it is meant to be heard as approval.

I would like to know where the actual lines are. Which of those refusals is a legal constraint on them, which is a commercial choice, and which of their claims is one they are not permitted to make? I would rather ask better questions than accuse anyone of anything.

One of the three was a commercial choice, one was a claim they may not make, and one was a phrase engineered to be misheard. Taking them in order.

"Which manufacturer supplies your API?"

Commercial choice, not a legal constraint. Nothing prevents a pharmacy from naming its API supplier, and pharmacies that are proud of their sourcing name it. What they are required to do is more specific and more useful to you: obtain a certificate of analysis for each lot of bulk drug substance, verify the supplier, and keep those records. So the question that gets a real answer is not "who is your supplier" but "may I see the COA for the API lot used in my preparation, and the release data for my finished lot?" That is a records request about your own dispensed medication, and a well-run pharmacy produces it. Note also that for a US 503A pharmacy the bulk substance is expected to be accompanied by a COA and, where applicable, come from an FDA-registered establishment — which is where the phrase in your third question comes from.

"Is your preparation equivalent to the branded product?"

This is the claim they may not make, and "delivers the same active ingredient" is a careful step to the side of it. Therapeutic equivalence is a specific regulatory determination that rests on an approved application and demonstrated bioequivalence. A compounded preparation has neither. It has not been through an approval process, no bioequivalence study has been run on it, and no agency has evaluated whether the vial delivers the same exposure as the pen. A pharmacy claiming equivalence is claiming something no one has tested.

Their actual sentence is defensible as far as it goes: the same active ingredient may well be present. What does not follow is the same delivered dose, the same pharmacokinetics, or the same clinical result. Different concentration, different excipients, different container, and a syringe rather than a metered pen are four independent reasons the delivered exposure can differ, and dose-response in this class is steep enough for that to matter — the trial programmes show clearly separated outcomes between adjacent dose steps [1] [2]. "Same molecule" and "same medicine" are not the same statement.

"Is it FDA approved?"

No, and it cannot be. Compounded preparations are by definition not FDA-approved drugs; the whole legal architecture is a set of exemptions from the approval requirement. "Our ingredients are FDA registered" is true and irrelevant in the same sentence: establishment registration means a facility told FDA it exists and is therefore subject to inspection. It is an administrative listing, not a finding about a product, and it says nothing about identity, potency, purity or safety. Any material shipped from a registered establishment can still be the wrong salt form at the wrong assay. When you see registration offered in answer to a question about approval, the substitution is the signal.

Where genuine legal constraints do bite

• No dispensing without a valid prescription for an individual patient, from a prescriber licensed where you are, with a real patient relationship. A site that will sell without one is not operating as a 503A pharmacy.
• Licensure where you are. Shipping into a state generally requires a non-resident pharmacy licence from that state's board. Ask for the number; verify it with the board rather than with the pharmacy.
• Clinical advice belongs to the pharmacist and the prescriber. A pharmacist can and should counsel you, but a customer-service agent choosing your dose is practising without a licence, and the good ones will hand you off rather than answer.
• They cannot represent a compounded preparation as approved, as bioequivalent, or as tested by FDA. Whatever their marketing implies, the sentence itself is not one they can defend.

Worth knowing for context: the statute originally contained an outright ban on advertising specific compounded drugs, and the Supreme Court struck that provision down on First Amendment grounds in 2002. So the reason you see aggressive marketing is not that anyone is ignoring the rule — that particular rule is gone. The constraints that remain are on the content of the claims, and those are the ones to hold them to.

The four questions that actually work

1. What is your state licence number in my state, and your PCAB or other accreditation status?
2. May I have the finished-preparation release data for my lot: identity, content assay, sterility, endotoxin?
3. What USP category was this assigned, what is the unpunctured BUD and the in-use limit, and what supports the BUD?
4. What is the exact substance name and form of the API, and what was its net peptide content?

Those are all answerable with documents, and the pattern of what comes back is more informative than any individual answer.

Adding what pharmacies are constrained towards, because the framing above is about refusals and there are affirmative duties that you can invoke.

A pharmacy dispensing to you generally owes you: an accurate label with the preparation name, strength, quantity, BUD, storage condition and lot; the statement that it is a compounded preparation, where applicable; an offer of counselling by a pharmacist, which in many states is mandatory rather than optional on new prescriptions; and access to your own records. That last one is the underused lever. A request for your dispensing record and the associated documentation for your own prescription is not a favour, and it is much harder to deflect than an open-ended question about their supply chain.

Put the request in writing and be specific about documents rather than reassurance. "Please provide the master formulation record reference, the compounding record for my lot, and any release testing performed on that lot" is a request a compliant pharmacy can fulfil from its own files, because it was required to create all three. If the answer is that no compounding record exists for your lot, that is not a communications problem.

One affirmative duty worth naming separately: in most jurisdictions a pharmacist must perform a prospective review for interactions, therapeutic duplication and dose appropriateness before dispensing, and must document it. That is a clinical check you are owed rather than a service you are buying, and asking what it flagged in your case is an entirely ordinary question — one that only an operation actually doing the review can answer.

A note on the telehealth-plus-pharmacy bundle, since that is how most people encounter this and it changes who you are actually talking to.

When a subscription platform ships you a compounded vial, there are usually three separate entities: the platform, an affiliated prescriber group, and a pharmacy. The platform is often the only one you can email. It is also the only one with no professional licence, and therefore the one least able to answer any of the questions in the accepted answer. Asking the platform for release data frequently produces a templated paragraph because the person replying has no route to the document.

The fix is to get the pharmacy's name and licence details off the vial label, which is required to be there, and correspond with the pharmacy directly as its patient. Likewise, get the prescriber's name and ask for a copy of the prescription. Both are yours. Once you are dealing with the licensed parties rather than the storefront, the questions land somewhere they can be answered, and the answers carry professional accountability that a customer-service reply does not.

One further consequence of the three-entity structure: the party with the deepest pockets and the loudest brand is usually the one with no clinical duty to you at all, while the party that does owe you a duty may be a small professional corporation whose name you have never seen. Find out which name is on the vial label and on the prescription before you need to know, because working it out during a problem is considerably harder.